Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa

AIDS

Volumn 21, Issue 18, 2007, Pages 2483-2491

  Moh, Raoul ^a   Danel, Christine ^a   Messou, Eugène ^a   Ouassa, Timothée ^a,b   Gabillard, Delphine ^a   Anzian, Amani ^a   Abo, Yao ^a   Salamon, Roger ^a,d   Bissagnene, Emmanuel ^a,c   Seyler, Catherine ^a,d   Eholié, Serge ^a,c   Anglaret, Xavier ^a,d  

^a Trivacan ANRS 1269 Study Group   (France)

^b CHU de Treichville   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^d INSERM   (France)

Author keywords

Antiretrovirals; Bacterial diseases; HAART; Morbidity; Risk factors; Sub Saharan Africa; Tuberculosis

Indexed keywords

ANTIVIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; HEMOGLOBIN; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; AFRICA; ARTICLE; BACTERIAL INFECTION; BODY MASS; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; IMMUNE DEFICIENCY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; THRUSH; TUBERCULOSIS; VIRUS DETECTION; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY MASS INDEX; CD4 LYMPHOCYTE COUNT; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HUMANS; MALE; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 36348986088     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f09876     Document Type: Article

References (34)

1. PEPFAR. Latest 2007 PEPFAR Treatment Results, 3/31/2007. http://www.pepfar.gov/press/85520.htm [Accessed 21 August 2007].
2. The Global Fund to fight AIDS team. Partners in Impact - Results Report 2007; http://www.theglobalfund.org/en/files/about/replenishment/oslo/ Progress%20Report.pdf [Accessed 21 August 2007].
3. WHO/UNAIDS/UNICEF. Towards Universal Access. Scaling up priority HIV/AIDS interventions in the health sector. Progress Report, April 2007. http://www.who.int/hiv/mediacentre/universal_access_progress_report_en.pdf [Accessed 21 August 2007].
4. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
5. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, Laniece I, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006; 20:1181-1189.
6. Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Touré S, Danel C, et al. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire. Antivir Ther 2003; 8:385-393.
7. Lawn SD, Bekker LG, Myer L, Orrell C, Wood R. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 2005; 19:2050-2052.
8. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605-1612.
9. Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-1989.
10. Danel C, Moh R, Anzian A, Abo Y, Chenal H, Guehi C, et al. Tolerance and acceptability of an efavirenz-based regimen in 740 adults (Predominantly women) in West Africa. J Acquir Immune Defic Syndr 2006; 42:29-35.
11. Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther 2005; 10:615-624.
12. Rouet F, Ekouevi DK, Chaix ML, Burgard M, Inwoley A, Tony TD, et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription - PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 2005; 43:2709-2717.
13. Anglaret X, Messou E, Ouassa T, Toure S, Dakoury-Dogbo N, Combe P, et al. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d'Ivoire. AIDS 2003; 17:575-584.
14. Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X. Risk factors for active tuberculosis following antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med 2005; 172:123-127.
15. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367:1335-1342.
16. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782-793.
17. Laurent C, Ngom Gueye NF, Ndour CT, Gueye PM, Diouf M, Diakhate N, et al. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr 2005; 38:14-17.
18. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006; 20:2355-2360.
19. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 2006; 20:1163-1169.
20. Weidle PJ, Wamai N, Solberg P, Liechty C, Sendagala S, Were W, et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 2006; 368:1587-1594.
21. Wester CW, Kim S, Bussmann H, Avalos A, Ndwapi N, Peter TF, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 2005; 40:336-343.
22. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-895.
23. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 3556:2283-2296.
24. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach. 2006 revision. http://www.who.int/hiv/pub/guidelines/WHO%20Adult%20ART%20Guidelines.pdf [Accessed 21 August 2007].
25. Badri M, Lawn S, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet 2006; 368:1254-1259.
26. World Health Organization. WHO expert consultation on cotrimoxazole prophylaxis in HIV infection. WHO technical report series. Reference number:WHO/HIV/2006.01. http://www.who.int/hiv/pub/meetingreports/ctx/en
27. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364:1428-1434.
28. Anglaret X, Chêne G, Attia A, Toure S, Lafont S, Combe P, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 1999; 353:1463-1468.
29. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006; 43:770-776.
30. Anastos K, Barron Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, et al. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med 2004; 140:256-264.
31. Lawn SD, Badri M, Wood R. Risk factors for tuberculosis among HIV-infected patients receiving antiretroviral treatment [letter]. Am J Respir Crit Care Med 2005; 172:1348; author reply 1348-1349.
32. Harries AD, Hargreaves NJ, Kwanjana JH, Salaniponi FM. Relapse and recurrent tuberculosis in the context of a national tuberculosis control programme. Trans R Soc Trop Med Hyg 2000; 94:247-249.
33. Balasubramanian VN, Oommen K, Samuel R. DOT or not? Direct observation of antituberculosis treatment and patient outcomes, Kerala State, India. Int J Tuberc Lung Dis 2000; 4:409-413.
34. Frieden TR. Lack of directly observed treatment affects tuberculosis relapse rates [letter]. Am J Respir Crit Care Med 2006; 173:359; author reply 359.